Our pharmacokinetic modeling suggests that for part of each day drug levels fell below the IC50 of 3 μg/ml defined for phospho-ERK (downstream effector of EGFR) in a xenograft cancer model [27]. The gene discussed is EGFR; the disease is cancer.